Ocular Therapeutix (OCUL) Cash & Equivalents (2013 - 2026)

Ocular Therapeutix has reported Cash & Equivalents for 14 years, with the latest figure at $598.6 million in Q2 2026.

• Cash & Equivalents for Q2 2026 came in at $598.6 million, up 53.05% year-over-year; the trailing twelve-month figure through Jun 2026 was $598.6 million (up 53.05% YoY), and the FY2025 annual result was $737.1 million, up 87.98% from the prior year.
• Cash & Equivalents declined to $598.6 million in Q2 2026, from $666.7 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $737.1 million in Q4 2025 and troughed at $66.6 million in Q2 2023.
• A 5-year average of $322.5 million and a median of $347.2 million in 2025 frame the typical range for Cash & Equivalents.
• The widest annual swing landed in 2023, when Cash & Equivalents slumped 50.49%; it then soared 590.16% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $102.3 million in 2022, then surged by 91.4% to $195.8 million in 2023, then soared by 100.25% to $392.1 million in 2024, then jumped by 87.98% to $737.1 million in 2025, then dropped by 18.78% to $598.6 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $598.6 million in Q2 2026, $666.7 million in Q1 2026, and $737.1 million in Q4 2025.